ARTICLE | Company News

Millennium, Structural GenomiX, Aventis deal

January 14, 2002 8:00 AM UTC

Structural will use its high throughput structural determination platform to support MLNM's selection and optimization of lead compounds. Structural will retain certain rights to use structural information of non-proprietary targets and may choose a validated drug target from MLNM's targets for its own drug discovery programs. MLNM will make an equity investment in Structural. ...